Multihance (Gadobenate Dimeglumine)

Multihance is a gadolinium‑based contrast agent used in magnetic resonance imaging to improve visualization of various anatomical regions.

• Brain and spinal cord MRI: Improves lesion detection and anatomical detail on T1‑weighted images.
• Liver MRI: Enhances lesion conspicuity and vascular phase imaging for hepatic assessment.
• Cardiovascular MRI: Provides high‑contrast delineation of cardiac chambers, myocardium and great vessels.
• Magnetic resonance angiography (MRA): Increases signal intensity of blood vessels for clearer angiographic studies.

• Gadobenate dimeglumine is a paramagnetic gadolinium chelate that shortens the T1 relaxation time of nearby water protons, thereby increasing signal intensity on T1‑weighted MRI sequences. Its partial binding to plasma proteins raises relaxivity, further amplifying contrast between vascular or tissue structures and surrounding background.

Adverse reactions may occur following intravenous administration of Multihance.

Common Side Effects

• Nausea: Mild to moderate feeling of stomach upset.
• Headache: Transient pain often resolving without intervention.
• Injection site discomfort: Burning or pain at the infusion site.
• Warmth sensation: Brief feeling of heat during injection.
• Dizziness: Light‑headedness that usually subsides quickly.
• Mild rash: Localized skin irritation.

Serious or Rare Side Effects

• Anaphylactic reaction: Severe allergic response requiring immediate medical attention.
• Nephrogenic systemic fibrosis (NSF): Fibrotic skin and organ changes in patients with severe renal impairment.
• Severe hypotension: Marked drop in blood pressure post‑injection.
• Cardiac arrest: Rare but life‑threatening cardiac event.
• Pulmonary edema: Accumulation of fluid in the lungs, especially in compromised patients.

Use of Multihance requires careful assessment of patient-specific factors.

• Renal function assessment: Evaluate glomerular filtration rate before administration.
• Pregnancy Category C: Use only if potential benefit justifies potential risk to the fetus.
• Breastfeeding caution: Consider discontinuing nursing or withholding the drug.
• Known gadolinium allergy: Avoid use in patients with documented hypersensitivity.
• Monitor for NSF: Particularly in patients with severe renal dysfunction.
• Pediatric use: Exercise caution and follow specialist guidance.
• Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Gadobenate dimeglumine may interact with other agents that affect renal function or gadolinium exposure.

Major Interactions (Avoid)

• Concurrent administration of other gadolinium‑based contrast agents: Increases cumulative gadolinium load.
• Use with nephrotoxic drugs (e.g., high‑dose aminoglycosides, iodinated contrast): Heightens risk of renal impairment.

Moderate Interactions (Monitor Closely)

• Loop diuretics: May alter renal clearance, requiring kidney function monitoring.
• Beta‑blockers: Can mask hypotensive reactions, necessitating blood pressure observation.
• Steroids: May reduce incidence of mild reactions but require monitoring for immunosuppression effects.